Technology | 2015.05.28
New Out Licensing Program for Liquid Biopsy Technology
Today, Proxy Life Science Holdings launched a patent licensing program for its Liquid Biopsy technology which promises not only to detect early disease but also to pinpoint affected organs. The company believes its seminal exosome RNA technology will become a key player in the Molecular Profiling space because of its application to a wide array of diseases including cancer, cardiovascular, immunological, metabolic and neurologic conditions.
(PRWeb May 28, 2015)
Read the full story at http://www.prweb.com/releases/2015/05/prweb12746842.htm
For more information, please visit
http://www.prweb.com/releases/2015/05/prweb12746842.htm
Instagram is adding automatic in-app text translation - The Verge views: 1531
Here’s a ‘Brand-New’ Massive Multilingual Dataset for Machine Translation views: 1530